Innovative Therapeutics Peel Therapeutics specializes in developing first-in-class neutrophil targeting peptides and plant toxin-based cancer drugs, highlighting potential for collaboration in advanced biologics and targeted therapies for oncology and inflammatory diseases.

Strong Funding Momentum With recent seed financing of 36 million dollars and additional non-dilutive grants, Peel Therapeutics demonstrates robust financial backing and a strong investor ecosystem, indicating readiness for further clinical development and commercialization efforts.

Clinical Advancement Having launched its first clinical study and progressing pipeline treatments for COVID-19, cancer, and inflammation, the company offers opportunities to partner in clinical research services, trial support, and regulatory strategy development.

Growth Focus With a relatively small team of up to 50 employees and expanding product pipelines, Peel Therapeutics is poised for strategic partnerships that can accelerate development timelines and bring innovative therapies to market.

Technology Infrastructure Utilizing cloud-based solutions like AWS and modern web technologies indicates an adoption of scalable digital infrastructure, opening avenues for software, data analytics, and bioinformatics collaborations that support drug discovery and development.